Accès ouvert · CC BY

Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer

Article scientifique 2021 Sciences de la vie et biotechnologies › Biotechnologies (OCDE 2.9) Anglais

Résumé

The estrogen receptor is a vital receptor for therapeutic targets in estrogen receptor-positive breast cancer. The main strategy for the treatment of estrogen receptor-positive breast cancers is blocking the estrogen action on estrogen receptors by endocrine therapy but this can be restricted via endocrine resistance. Endocrine resistance occurs due to both de novo and acquired resistance. This review focuses on the mechanisms of the ligand-dependent and ligand-independent pathways and other coregulators, which are responsible for endocrine resistance. It concludes that combinatorial drugs that target different signaling pathways and coregulatory proteins together with endocrine therapy could be a novel therapeutic modality to stop endocrine resistance.

Citer ce document

Belachew, E. B., & Sewasew, D. T. (2021). Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2021.599586

Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)

Accès au document

Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter

Voir l'article sur le site de la revue

Licence et provenance

Licence : CC BY

Notice moissonnée depuis OpenAlex le 05/09/2026. Le document reste hébergé par sa source.
Voir le document à la source →

Statistiques

Consultations (hors robots) : 13

Téléchargements (hors robots) : 0

Méthode de comptage